I
INNATE PHARMA
NASDAQ: IPHA (Innate Pharma S.A.)
Kemas kini terakhir: 26 minit lalu1.39
-0.07 (-4.79%)
| Penutupan Terdahulu | 1.46 |
| Jumlah Dagangan | 32,673 |
| Harga / Jualan (P/S) | 27.52 |
| Julat 52 Minggu |
| Margin Keuntungan | -245.87% |
| Margin Operasi (TTM) | -324.87% |
| EPS Cair (TTM) | -0.710 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -63.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 350.86% |
| Nisbah Semasa (MRQ) | 2.60 |
| Aliran Tunai Operasi (OCF TTM) | -6.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 17.12 M |
| Pulangan Atas Aset (ROA TTM) | -22.52% |
| Pulangan Atas Ekuiti (ROE TTM) | -162.91% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Innate Pharma S.A. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.7 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -0.5 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.43 |
|
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Institusi | 0.24% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lion Point Capital, Lp | 30 Jun 2026 | 81,151 |
| Smartharvest Portfolios, Llc | 30 Sep 2026 | 20,868 |
| Rhumbline Advisers | 30 Jun 2026 | 4,719 |
| Farther Finance Advisors, Llc | 30 Sep 2026 | 10 |
| Gamma Investing Llc | 30 Sep 2026 | 9 |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |